Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 11Phase 1/2 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × trebananib × Clear all
NCT01290263 2017-07-02

Amgen 386 for Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
48 enrolled 13 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT01666977 2016-06-03

Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

Amgen

Phase 1/2 Completed
36 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡